People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Pharma, Other Technology, Energy / Climate, Mining & Resources, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Soleno Therapeutics Inc | — | Pharma | Series C | $98.6M | $680.0M | 2023 |
| Ironkey Inc | — | Other Technology | Series B | $34.6M | $670.0M | 2009 |
| Encore Energy Corp. | — | Energy / Climate | Series B | $19.4M | $135.4M | 2019 |
| Scandium International Mining Corp. | — | Mining & Resources | Seed | $12.4M | $511K | 2009 |
| SafeCorp Financial Corp | — | Other Technology | Series A | $10.0M | $277.4M | 2010 |
| Golden Predator Corp. | — | Other | Seed | $9.7M | $20.7M | 2009 |
| Yodlee Inc | — | Other Technology | Series A | $8.3M | $230.5M | 2012 |
| Center'd Corp | — | Other Technology | Seed | $3.4M | $51.1M | 2009 |
| Triumph Gold Corp. | — | Mining & Resources | Seed | $3.3M | $452K | 2011 |
William Harris at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside William Harris on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| William Sheriff | 3 | 8 |
| William B. Harris | 3 | 5 |
| William M. Sheriff | 2 | 7 |
| Steve Vanry | 2 | 6 |
| Bill Harris | 2 | 3 |
| Art Ettlinger | 2 | 2 |
| Christine Thomson | 2 | 2 |
| Nancy La Couvee | 2 | 2 |
| John Anderson | 1 | 22 |
| John Thompson | 1 | 13 |
| Scott Davis | 1 | 10 |
| Paul Matysek | 1 | 10 |
| Greg Johnson | 1 | 9 |
| Ernest Mario | 1 | 9 |
| Gregory Johnson | 1 | 8 |
| Matthew Cowan | 1 | 7 |
| Connie Norman | 1 | 6 |
| JON FEIBER | 1 | 5 |
| James Feuille | 1 | 5 |
| Edgar G Engleman | 1 | 5 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.